News
Novel PCOS treatment shows ‘great promise’ in clinical trials
The Ovarian Rebalancing treatment aims to lower androgen production through targeted ovarian ablation
A French medical device company has unveiled promising clinical trial results for a “novel” polycystic ovary syndrome treatment.
May Health has announced preliminary data supporting the safety and effectiveness of its Ovarian Rebalancing treatment for inducing ovulation in women with PCOS-related infertility at the this year’s ESHRE meeting in Copenhagen.
The company has received the US FDA’s approval of its REBALANCE study, designed to evaluate the safety and effectiveness of Ovarian Rebalancing in women with PCOS-related infertility.
PCOS is a common condition affecting around one in 10 women in the UK.
Women with PCOS may experience symptoms such as irregular periods, high levels of “male” hormones, known as androgens, and a cystic appearance of the ovaries on ultrasound caused by the ovarian follicles becoming arrested in their development towards releasing an egg.
The “novel” one-time treatment aims to lower androgen production, which can often restore ovulation, through targeted ovarian ablation.
Saad Amer, professor of gynaecology and reproductive medicine at the University of Nottingham and lead investigator, said: “Infertility is an emotional journey, and current options available to achieve pregnancy are often expensive, invasive, and do not work for all women, adding burden to the experience.
“The new data shows great promise for Ovarian Rebalancing as a safe and effective office-based treatment to induce ovulation in women who have not achieved results from first-line medications.”
To date, a pregnancy rate of 35 per cent was observed for the 23 participants who received Ovarian Rebalancing and completed six months of follow-up, including some patients who re-started first-line ovulation induction medication between three and six months, the trials found.
Results showed 44 per cent of women ovulated spontaneously during the first three months after undergoing Ovarian Rebalancing.
The trials also showed the ovulation rate increased to 65 per cent between three and six months, with the re-introduction of first-line medication at three months post procedure.
In 100 per cent of patients, ablation was achieved successfully in at least one ovary, the studies found, with 84 per cent of patients receiving the targeted ablation in both ovaries.
No serious adverse events related to the device were reported. The most common adverse events related to the procedure were mild and included vaginal bleeding, pain, and headache.
Anne Morrissey, CEO of May Health, said: “In addition to being the leading cause of infertility, PCOS causes other major health challenges and women lack options to address the needs of this disorder.
“Our team recognises the need for innovative treatments for PCOS, and the data from our trials show that Ovarian Rebalancing has the potential to shift the treatment landscape for this patient population.
“We are eager to continue our research with the US pivotal trial and explore additional endpoints in future studies to assess the potential of Ovarian Rebalancing as a treatment for other symptoms of PCOS.”
Antoine Papiernik, chairman and managing partner of Sofinnova Partners, said: “The inception of May Health within our medtech accelerator was fuelled by a firm belief in the transformative potential of its technology.
“The success of these feasibility studies and the FDA’s approval of the pivotal REBALANCE study only serve to reinforce our initial conviction. We look forward to seeing this technology revolutionise the field of infertility treatment.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment